Mohs vs radiation therapy for skin cancer: how the two compare

For most patients who can undergo surgery, Mohs offers a higher cure rate than radiation therapy for basal and squamous cell carcinoma, and it is the only option that proves the margins are clear on the day of treatment. Radiation remains a genuinely valuable tool, but it occupies a specific place: patients who cannot have surgery, tumors in locations where surgery would be unusually destructive, and select cases where it supplements surgery rather than replacing it.

The two treatments answer the central question differently. The central question in any skin cancer treatment is whether every last extension of the tumor has been eliminated. Mohs answers it directly, by examining essentially the entire margin under the microscope before the wound is closed. Radiation answers it statistically: the beam covers the visible tumor plus a calculated safety zone, and success is confirmed only by watching the site over the following years. That difference, verified clearance versus probabilistic clearance, is the root of the cure rate gap.

The numbers favor surgery for most primary tumors. Long-term studies report cure rates around 99 percent for primary basal cell carcinoma treated with Mohs, a figure with real context behind it, while modern radiation series for comparable tumors generally land around 90 to 95 percent. A randomized trial comparing surgery with radiotherapy for facial basal cell carcinoma, published in the British Journal of Cancer, found fewer recurrences and better-rated cosmetic results in the surgical group at four years. Radiation cosmesis also behaves differently over time: a radiated site can look excellent at one year and then slowly develop thinning, lightening, and small surface vessels over a decade or more, whereas a surgical scar tends to improve and then stay put.

Radiation earns its place where surgery struggles. For patients who are too frail for even local-anesthetic surgery, who take medications that make any procedure risky, or who simply decline an operation, radiation offers curative-intent treatment with no incision at all. It can be preferred for some tumors in locations where removing tissue carries a high functional price. It also plays a supporting role after surgery: when pathology shows perineural invasion or other high-risk features in a squamous cell carcinoma, radiation to the surgical site can lower the chance of recurrence. The American Academy of Dermatology notes that treatment for these cancers should always be matched to the tumor's individual risk profile, and that matching is exactly where radiation enters the conversation.

The practical trade-offs go beyond cure rates. Mohs is one long day; radiation is typically 15 to 30 short visits spread over three to six weeks, a meaningful burden for anyone who travels far for care. Mohs leaves a surgical scar; radiation avoids one but can cause temporary skin irritation during treatment and permanent skin changes later. One less obvious asymmetry matters for younger patients: skin that has been radiated heals less well ever after, so surgeons prefer not to operate through an old radiation field if a recurrence appears, while operating first preserves every future option, including radiation if it is ever needed. This is one reason guidelines generally reserve radiation for patients over 60 unless surgery is truly not an option.

For recurrent tumors, surgery holds a clear edge. A cancer that regrows after radiation tends to be harder to define and more aggressive, and it cannot simply be radiated again in the same spot. Mohs, with its complete margin control, is the standard rescue for these cases, just as it is for cancers that return after a previous excision.

The honest summary for patients: if you are a reasonable surgical candidate with a basal or squamous cell carcinoma that meets the criteria for Mohs, surgery offers the better cure rate, a single-day timeline, and proof of clearance before you leave. If surgery is not realistic for you, radiation is a legitimate, well-established alternative with decades of results behind it, not a consolation prize. The right forum for the choice is a candid conversation with a dermatologic surgeon, and where the decision is close, asking both a Mohs surgeon and a radiation oncologist to make their case is time well spent.

Related reading: Mohs surgery vs standard excision: what is the difference?